---
document_datetime: 2026-02-06 15:54:23
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tepkinly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: tepkinly-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.7283061
conversion_datetime: 2026-02-09 22:04:14.223504
docling_version:
  docling-serve: 1.12.0
  docling-jobkit: 1.10.1
  docling: 2.72.0
  docling-core: 2.63.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Tepkinly

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number     | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|------------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type IA_IN / | C.3 Change(s) in the summary of product | 06/02/2026                          |                                             | SmPC and PL                      | To update sections 4.4 and 4.8 of the SmPC and |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000325305                     | characteristics, labelling or package leaflet intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Article 45 or 46 of Regulation (EC) No 1901/2006, or the outcome of a PRAC signal recommendation, or to adapt to a joint recommendation of EU competent authorities (e.g. a Core SmPC, or following the assessment of an Urgent Safety Restriction etc.) - C.3.a) Implementation of the agreed wording - Accepted   |            |            |             | sections 2 and 4 of the PL to implement the signal recommendations on 'hypogammaglobulinaemia (EPITT no. 20174)' adopted at the 30 October 2025 PRAC.                                                                                                                                                                                                                                                                                                                              |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 1 year / EMA/R/0000257200   | - Renewal - Accepted Renewal of marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 22/05/2025 | 17/07/2025 | SmPC and PL | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for Tepkinly, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| Variation type II / EMA/VR/0000296114 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant                                                                                                                                                                                                                      | 27/11/2025 |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|                                       | assessment by the competent authority is required* - Accepted Submission of an updated RMP version 3.0 in order to amend the important identified risk of serious infections to now encompass progressive multifocal leukoencephalopathy (PML).                                                                                                                                                                                         |            |             |            |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|------------|
| PSUR / EMA/PSUR/0000282231            | In view of available data on haemophagocytic lymphohistiocystosis (HLH) from clinical trial(s), the literature, spontaneous reports, and in view of a plausible mechanism of action, the PRAC Rapporteur considers a causal relationship between epcoritamab and HLH is at least a reasonable possibility. The PRAC Rapporteur concluded that the product information of products containing epcoritamab should be amended accordingly. | 13/11/2025 | SmPC and PL | Variation. |
| Variation type IB / EMA/VR/0000291328 | This was an application for a group of variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant                                                                                                         | 09/09/2025 |             |            |

<div style=\"page-break-after: always\"></div>

|                                       | quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted   |            |             |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| Variation type II / EMA/VR/0000280386 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of sections 4.2 and 4.4 of the SmPC in order to modify instructions based on results from study M23-362; this is a Phase 2, open-label study to evaluate adverse events of subcutaneous epcoritamab administered in the outpatient setting in                                                                                                                                                                                                                                                          | 04/12/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

| adult participants with R/R DLBCL and classic FL. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the Product Information.   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|